Anticoagulation in Pediatrics: DOACs on the Horizon

Jasmine Manning, PharmD Candidate 2019; Diane Nykamp, PharmD

Disclosures

US Pharmacist. 2019;44(5):HS8-HS12. 

In This Article

Conclusion

The advantages of DOACs include oral dosage formulations, such as a suspension currently under study, minimal monitoring requirements, predictable pharmacokinetics, and no food interactions. Current guidelines for antithrombotic therapy in pediatric patients do not include recommendations for the use of DOACs. Current trials evaluating the safety and efficacy of DOAC therapy should, in the future, provide physicians and pharmacists with additional drug-therapy options and data to help guide and optimize anticoagulant therapy for pediatric patients.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....